![Gabriela Nicolau](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gabriela Nicolau
Corporate Officer/Principal bei Tetragenex Pharmaceuticals, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David Abel | M | 79 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 Jahre |
Martin F. Schacker | M | 65 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 Jahre |
William T. Comer | M | 85 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 Jahre |
Bruce J. Bergman | M | 76 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 30 Jahre |
Alf E. F. Akerman | M | 58 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 Jahre |
Kenneth Cartwright | M | 86 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 35 Jahre |
Aaron S. Cohen | M | 87 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 23 Jahre |
Jacques Turgeon | M | - |
International Society for the Study of Xenobiotics
| - |
Kei-Lai L. Fong | M | - |
International Society for the Study of Xenobiotics
| - |
Joseph J. Hlavka | M | - |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 31 Jahre |
Richard J. Ablin | M | - |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 33 Jahre |
Andrew Dahlem | M | 64 |
International Society for the Study of Xenobiotics
| - |
Barry H. Dvorchik | M | - |
International Society for the Study of Xenobiotics
| - |
Geoffrey Thomas Tucker | M | - |
International Society for the Study of Xenobiotics
| 10 Jahre |
Robert Peter Budetti | M | 79 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 25 Jahre |
William P. Duncan | M | - |
International Society for the Study of Xenobiotics
| - |
Jinn Wu | M | 75 |
International Society for the Study of Xenobiotics
| - |
Shane R. Needham | M | - |
International Society for the Study of Xenobiotics
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Dov Elefant | M | 56 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 8 Jahre |
Neil Martucci | M | 49 |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 9 Jahre |
Jose Barak | M | 78 |
University of Bucharest
| 5 Jahre |
John P. Feighner | M | - |
Tetragenex Pharmaceuticals, Inc.
![]() Tetragenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetragenex Pharmaceuticals, Inc. operates as a biotechnology company. It develops and commercializes proprietary pharmaceutical products for use in treatment resistant depression and other central nervous system diseases in the United States. The firm's principal product is Nemifitide, an antidepressant compound, which is in Phase II clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. The company was founded in 1989 and is headquartered in Syosset, NY. | 7 Jahre |
Dumitru Manoiu | M | - |
University of Bucharest
| 3 Jahre |
Nicolae Radu | M | 75 |
University of Bucharest
| 5 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 21 | 87,50% |
Rumänien | 3 | 12,50% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Gabriela Nicolau
- Persönliches Netzwerk